Matthew Arnold

The paper uses polygenic scores to identify plasma proteins causally linked to cardiometabolic diseases and finds some are targets for existing therapies.

This study evaluates how adding polygenic risk scores and clinical biochemistry markers to conventional CVD risk models improves prediction accuracy and informs statin therapy decisions in a UK primary care setting.